Overview

Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

Status:
Completed

Trial end date:
2004-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the vasoconstriction response profile and bioequivalence between one innovator lot of Ultravate® 0.05% ointment and one test/generic lot of Halobetasol propionate 0.05% ointment (Alpharma USPD, Inc.).

Phase:

Phase 1

Details

Lead Sponsor:

Actavis Inc.

Treatments:

Clobetasol
Halobetasol